Which option best describes what the introduction to nonclinical pharmacology should include?

• A. It should only summarize safety
• B. It should incorporate studies that assess potential therapeutic activity as well as safety
• C. It should focus only on reproductive toxicity
• D. It should exclude any pharmacology data

Answer: (B)

Nonclinical pharmacology looks at both how the drug works and what safety concerns may arise, to build a complete picture before testing in people. The introduction should lay out how the compound is expected to exert therapeutic effects (pharmacodynamics) and what safety signals have been observed (toxicology and safety pharmacology), along with how exposure relates to effect. This provides the scientific rationale for moving into human studies, helps with initial dose selection, and identifies potential risks to monitor in later phases.

So the best description is that it incorporates studies that assess potential therapeutic activity as well as safety. It stays away from being narrowly focused on one aspect, and it isn’t limited to a single safety endpoint or excluded from pharmacology data altogether.